Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Reblozyl | luspatercept | beta-thalassemia associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete | ||
Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete | ||
Remicade | Infliximab | Ulcerative Colitis | Do not list | Complete | ||
Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | Do not list | Complete | ||
Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | ||
Remsima | infliximab | Crohn’s disease | Active | |||
Remsima | infliximab | Ulcerative Colitis | Active | |||
Remsima | infliximab | Rheumatoid arthritis | Reimburse with clinical criteria and/or conditions | Complete |